GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Nephron, S. Karger AG, Vol. 92, No. 3 ( 2002), p. 735-737
    Abstract: 〈 i 〉 Background: 〈 /i 〉 Chronic renal failure is commonly associated with disturbances in hypothalamic-pituitary-gonadal function. 〈 i 〉 Methods: 〈 /i 〉 The gonadotrophins, prolactin and estradiol or testosterone levels were measured immediately before renal transplantation, at discharge from the transplantation unit (19 ± 8 days after Tx) and 6 months after transplantation in 21 patients, 7 females and 14 males, age range 21–60 years. 〈 i 〉 Results: 〈 /i 〉 The mean prolactin level was high during uremia and decreased rapidly after transplantation, from 441 to 167 mU/l in males and from 1,057 to 521 mU/l in females. Hypergonadotrophism was seen in most uremic patients, with the mean LH and FSH levels of 14.2 and 6.0 U/l in males and 14.7 and 4.0 U/l in females, respectively. A temporary change to hypogonadotrophic hypogonadism took place 2–3 weeks after transplantation and was followed by normalization of the hypothalamic-gonadal function. The levels of circulating sex steroids were suppressed when the patients were discharged from the transplantation unit but returned to the normal range at 6 months. 〈 i 〉 Conclusions: 〈 /i 〉 We conclude that renal transplantation corrects the hyperprolactinemia induced by uremia and is followed by rapid onset of restoration of the hypothalamic-pituitary-gonadal axis.
    Type of Medium: Online Resource
    ISSN: 1660-8151 , 2235-3186
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2002
    detail.hit.zdb_id: 2810853-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Elsevier BV ; 1999
    In:  Kidney International Vol. 55, No. 3 ( 1999-03), p. 1091-1096
    In: Kidney International, Elsevier BV, Vol. 55, No. 3 ( 1999-03), p. 1091-1096
    Type of Medium: Online Resource
    ISSN: 0085-2538
    Language: English
    Publisher: Elsevier BV
    Publication Date: 1999
    detail.hit.zdb_id: 2007940-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Nephron Clinical Practice, S. Karger AG, Vol. 108, No. 4 ( 2008-4-22), p. c284-c290
    Abstract: 〈 i 〉 Background/Aim: 〈 /i 〉 Knowledge of the usefulness of cystatin C measurement in the detection of chronic kidney disease in patients with rheumatoid arthritis (RA) is scant. The purpose of this study was to evaluate the ability of plasma cystatin C- and creatinine-based methods to predict glomerular filtration rate (GFR) and classify chronic kidney disease in RA patients. 〈 i 〉 Methods: 〈 /i 〉 The study population consisted of 64 RA patients aged 41–86 years. Comparisons were made between measured plasma creatinine, cystatin C, creatinine clearance and GFR estimated by the Cockcroft-Gault (CG) and the Modification of Diet in Renal Disease (MDRD) formulas. The plasma clearance of 〈 sup 〉 51 〈 /sup 〉 Cr-EDTA served as a reference. 〈 i 〉 Results: 〈 /i 〉 The Pearson correlation coefficients between plasma clearance of 〈 sup 〉 51 〈 /sup 〉 Cr-EDTA and the markers of GFR were calculated. The correlation coefficients were 0.800 for plasma creatinine, 0.863 for cystatin C, 0.866 and 0.904 for GFR values estimated by MDRD and CG and 0.922 for plasma creatinine clearance. Statistically significant differences were detected between the correlation coefficients of plasma creatinine and GFR estimated by CG (p = 0.0412) and plasma creatinine and creatinine clearance (p = 0.0099). Creatinine clearance and the MDRD and CG formulas proved to be better at identifying GFR 〈 90 ml/min than plasma creatinine or cystatin C. 〈 i 〉 Conclusion: 〈 /i 〉 We recommend using the CG formula or creatinine clearance for the estimation of the GFR of RA patients instead of solely creatinine or cystatin C in clinical work.
    Type of Medium: Online Resource
    ISSN: 1660-2110
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2008
    detail.hit.zdb_id: 2098336-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    SAGE Publications ; 1997
    In:  Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Vol. 17, No. 4 ( 1997-07), p. 347-352
    In: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, SAGE Publications, Vol. 17, No. 4 ( 1997-07), p. 347-352
    Abstract: To evaluate the magnesium status of continuous ambulatory peritoneal dialysis (CAPD) patients using a new method for assessing the level of the ionized fraction a serume magnesiumy. Design Serum ionized magnesium was measured in CAPD patients using the ion-selective electrode for Mg2+. Setting The Dialysis Unit of Tampere University Hospital. Patients Twenty -six patients on CAPD (age: 21 -81 years, mean 54 ± 16 years; duration of CAPD: 3 -52 months, mean 13 months), and 26 sex and age-matched healthy controls. Results Both serum ionized magnesium (0.73 ± 0.11 mmol/L vs 0.56 ± 0.07 mmol/L, p 〈 0.001) and total magnesium (1.11 ± 0.22 vs 0.81 ± 0.08 mmol/L, p 〈 0.01) were higher in CAPD patients than in sex and agematched controls. The ionized magnesium fraction of total magnesium was slightly lower in dialysis patients in spite of the fact that 16/26 patients had serum albumin less than 36 g/L. Hypermagnesemia (mean serum ionized magnesium 0.78± 0.10 mmol/L) was observed in the 13 of 26 patients with 0.75 mmol/L Mg2+ dialysate; those with lower magnesium dialysate (Mg2+ 0.50 mmol/L in 10/26 and Mg2+ 0.25 mmol/L in 3/26) had mean serum ionized magnesium at the upper normal margin (0.69 ± 0.10 mmol/L). Conclusion In CAPD patients with Mg2+ 0.5 0.75 mmol/L in their dialysis fluid, both serum ionized and total magnesium concentrations were higher but the ionized/total magnesium ratio was lower than in healthy control subjects. Use of ion-selective electrodes to measure ionized magnesium may be a more useful methodology than measuring total magnesium in the evaluation of magnesium status of CAPD patients, because it is not infuenced by hypoalbuminemia or increased complexed fraction of magnesium often present in dialysis patients.
    Type of Medium: Online Resource
    ISSN: 0896-8608 , 1718-4304
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1997
    detail.hit.zdb_id: 2075957-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    SAGE Publications ; 2007
    In:  Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Vol. 27, No. 2_suppl ( 2007-06), p. 210-214
    In: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, SAGE Publications, Vol. 27, No. 2_suppl ( 2007-06), p. 210-214
    Abstract: In the present article, we review current knowledge of the epidemiology, diagnosis, and treatment of peripheral vascular disease in patients with end-stage renal disease. The main focus is placed on diabetic patients receiving peritoneal dialysis, but studies on patients receiving hemodialysis are also reviewed, because most reports involve this patient group, and the number of reports on peripheral vascular disease in PD patients alone is limited.
    Type of Medium: Online Resource
    ISSN: 0896-8608 , 1718-4304
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2007
    detail.hit.zdb_id: 2075957-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Nephron, S. Karger AG, Vol. 86, No. 2 ( 2000), p. 139-144
    Abstract: 〈 i 〉 Background/Aims: 〈 /i 〉 In vitro constant calcitriol [1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 ] inhibits healthy individuals’ T lymphocyte proliferation at supraphysiological concentrations. In contrast, among hemodialysis patients, intravenous 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 pulse therapy of secondary hyperparathyroidism has been shown to be even immunostimulatory. We studied the effect of in vitro constant and intermittent 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 on lymphocyte antigen response of hemodialysis patients. 〈 i 〉 Methods: 〈 /i 〉 Twelve hemodialysis patients’ peripheral blood mononuclear cells were stimulated with purified protein derivative of tuberculin (12.5, 25 and 50 mg/l) or tetanus toxoid (TT; 1,000, 5,000 and 10,000 Lf/l, limit of flocculation) for 7 days. Constant 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 was added to all cultures at concentrations of 0, 10 〈 sup 〉 –10 〈 /sup 〉 or 0.25 × 10 〈 sup 〉 –9 〈 /sup 〉 mol/l (0, 42 and 105 ng/l) and to half of the cultures additionally as a 0.75 × 10 〈 sup 〉 –9 〈 /sup 〉 mmol/l (315-ng/l) pulse on the 5th culture day. 〈 i 〉 Results: 〈 /i 〉 TT-induced lymphocyte proliferation was statistically related to a constant 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 concentration (p = 0.001, analysis of variance). With constant 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 concentrations of 0, 42 and 105 ng/l, the TT-induced responses were 1.53, 1.44 and 1.40 log cpm, respectively (mean of TT concentrations). The responses of the (additionally) pulse-treated cells [1.65, 1.50 and 1.40 log cpm; concentrations of constant 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 as above] were similar to those of the nonpulsed cells. Thus constant, but not pulsed 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 decreased the TT responses. On the purified protein derivative of tuberculin response, neither constant nor pulsed 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 had any significant effect. 〈 i 〉 Conclusions: 〈 /i 〉 The decline of TT response with constant 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 corresponds with findings on immunosuppressive action of 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 in previous studies done on normal subjects’ cells. This was not seen with intermittently applied 1,25-(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 . These results support the previous concept that intermittent 1,25(OH) 〈 sub 〉 2 〈 /sub 〉 D 〈 sub 〉 3 〈 /sub 〉 therapy is not immunosuppressive in hemodialysis patients.
    Type of Medium: Online Resource
    ISSN: 1660-8151 , 2235-3186
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2000
    detail.hit.zdb_id: 2810853-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Nephron, S. Karger AG, Vol. 86, No. 1 ( 2000), p. 56-61
    Abstract: 〈 i 〉 Background: 〈 /i 〉 Hemodialysis (HD) patients are immunocompromised, and they have been shown to react suboptimally to recommended vaccinations. Advances in dialysis therapy and other supportive measures may theoretically result in better immune system functions. Clinical evidence supporting this theory has, however, not been presented. With influenza vaccination response, we tried to address this question. 〈 i 〉 Methods: 〈 /i 〉 42 HD and 15 continuous ambulatory peritoneal dialysis (CAPD) patients were vaccinated with a trivalent influenza vaccine, and the seroresponses at 5 weeks were measured. The results were compared with those of similarly vaccinated 20 nephrology outpatient clinic patients with varying degrees of renal insufficiency and those of 31 cardiac patients with normal renal function. 〈 i 〉 Results: 〈 /i 〉 The dialysis patients had higher prevaccination titers of hemagglutination-inhibiting (HI) antibodies to all three vaccine virus antigens than the other groups due to more frequent previous vaccinations. The dialysis patients exhibited lower antibody increases, but an almost comparable proportion of them reached a protective antibody level (HI titers ≧40) 5 weeks after vaccination [A/H3N2: 61% (cardiac patients), 35% (nephrology outpatient clinic patients), 67% (CAPD), and 36% (HD); A/H1N1: 71, 70, 80 and 60; B: 97, 90, 80, and 76%, respectively] . Among the HD group, all patients receiving parenteral calcitriol except 1 (83%), but only 50% of the other HD patients produced protective antibody titers at least to two out of three vaccine virus antigens. No other patient- or HD treatment-associated parameter was significantly related to the vaccination-induced antibody response. 〈 i 〉 Conclusions: 〈 /i 〉 We conclude that influenza vaccination of dialysis patients according to current recommendations may be effective. Additionally, our results suggest that parenteral calcitriol treatment may augment the immune response of HD patients even in a clinically relevant way, an effect so far shown only in in vitro studies.
    Type of Medium: Online Resource
    ISSN: 1660-8151 , 2235-3186
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2000
    detail.hit.zdb_id: 2810853-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    SAGE Publications ; 1998
    In:  Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Vol. 18, No. 2 ( 1998-03), p. 204-209
    In: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, SAGE Publications, Vol. 18, No. 2 ( 1998-03), p. 204-209
    Abstract: To study the pharmacokinetics of clodronate in patients on continuous ambulatory peritoneal dialysis (CAPD). Design A single intravenous dose pharmacokinetic study. Setting University hospital. Patients Ten CAPD patients (3 female, 7 male, age 39 79 year, median 55). Methods Clodronate disodium in serum, urine, and dialysate was collected for 24 hours and analyzed by capillary gas chromatography with mass-selective detection. Results Only 7% of the infused dose of clodronate was eliminated through peritoneal dialysis during 24 hours. Clearance via CAPD (CLCAPD) was 2.4 ± 0.6 mL/min, which was less than 10% of the total serum clearance (CLtot’ 26.0 ± 19.3 mL/min). Even the kidneys were a more important route of elimination than CAPD in those patients with residual diuresis of more than 500 mL/24 hr. However, in all patients most of the clodronate serum clearance (77% ± 13%) took place via routes other than peritoneal dialysis or kidneys, that is, via nonrenal-non-CAPD clearance (CLNRD). CLNRD most likely represents the part of the drug deposited in the skeleton. There was a positive correlation between CLNRD and the plasma intact parathyroid hormone concentration. Conclusions CAPD removed clodronate poorly from the circulation. Most clearance took place via routes other than CAPD or kidneys. This CLNRD most likely represents the skeletal deposition of the drug, and this is related to the severity of hyperparathyroidism. When treating CAPD patients with hyperparathyroid bone disease, the administration of clodronate should be adjusted as in those subjects with severe renal failure.
    Type of Medium: Online Resource
    ISSN: 0896-8608 , 1718-4304
    Language: English
    Publisher: SAGE Publications
    Publication Date: 1998
    detail.hit.zdb_id: 2075957-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Kidney International, Elsevier BV, Vol. 74, No. 3 ( 2008-08), p. 319-327
    Type of Medium: Online Resource
    ISSN: 0085-2538
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2008
    detail.hit.zdb_id: 2007940-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Elsevier BV ; 2000
    In:  Kidney International Vol. 57, No. 5 ( 2000-05), p. 2117-2122
    In: Kidney International, Elsevier BV, Vol. 57, No. 5 ( 2000-05), p. 2117-2122
    Type of Medium: Online Resource
    ISSN: 0085-2538
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2000
    detail.hit.zdb_id: 2007940-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...